 | • レポートコード：D005-09017 • 出版社/出版日：GlobalInfoResearch / 2020年5月22日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール • 産業分類：医療・製薬 |
| Single User | ￥522,000 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥783,000 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,044,000 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、下痢を伴う過敏性腸症候群（IBS-D）薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。下痢を伴う過敏性腸症候群（IBS-D）薬の種類別市場規模（エルキサドリン、アロセトロン、リファキシミン、ロペラミド、ジフェノキシレート+アトロピン、ジシクロミン＆ヒヨスチアミン）、用途別市場規模（病院、クリニック、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、メーカー別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・市場概要 ・メーカー情報（販売量、市場シェア、製品概要、SWOT分析）：Astellas Pharmaceuticals、GlaxoSmithKline、Actavis、Pfizer、AstraZenenca、Salix Pharmaceuticals Ltd ・地域別グローバル市場分析 2015年-2020年 ・下痢を伴う過敏性腸症候群（IBS-D）薬の北米市場（アメリカ、カナダ、メキシコ） ・下痢を伴う過敏性腸症候群（IBS-D）薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・下痢を伴う過敏性腸症候群（IBS-D）薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・下痢を伴う過敏性腸症候群（IBS-D）薬の南米市場（ブラジル、アルゼンチン） ・下痢を伴う過敏性腸症候群（IBS-D）薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：エルキサドリン、アロセトロン、リファキシミン、ロペラミド、ジフェノキシレート+アトロピン、ジシクロミン＆ヒヨスチアミン ・用途別分析：病院、クリニック、その他 ・地域別市場規模予測 2021年-2025年 ・販売チャネル、流通業者、代理店 ・調査の結果・結論 |
Market Overview
The global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market has been segmented into
Preface
Eluxadoline
Alosetron
Rifaximin
Loperamide
Diphenoxylate + Atropine
Dicyclomine and Hyoscyamine
By Application, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs has been segmented into:
Hospitals
Clinics
Others
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market presented in the report. This section sheds light on the sales growth of different regional and country-level Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market.
The report offers in-depth assessment of the growth and other aspects of the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, etc.)
Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa)
Competitive Landscape and Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Analysis
Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales, revenue and market share for each player covered in this report.
The major players covered in Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs are:
Astellas Pharmaceuticals
GlaxoSmithKline
Actavis
Pfizer
AstraZenenca
Salix Pharmaceuticals Ltd
Among other players domestic and global, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately. Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs, with price, sales, revenue and global market share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs in 2018 and 2019.
Chapter 3, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.
Chapter 12, Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.
Chapter 13, 14 and 15, to describe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Table of Contents
1 Market Overview
1.1 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Preface
1.2.3 Eluxadoline
1.2.4 Alosetron
1.2.5 Rifaximin
1.2.6 Loperamide
1.2.7 Diphenoxylate + Atropine
1.2.8 Dicyclomine and Hyoscyamine
1.3 Market Analysis by Application
1.3.1 Overview: Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Overview of Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market
1.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Outlook (2015-2025)
1.4.2 North America (United States, Canada and Mexico)
1.4.3 Europe (Germany, France, United Kingdom, Russia and Italy)
1.4.4 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.5 South America, Middle East & Africa
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astellas Pharmaceuticals
2.1.1 Astellas Pharmaceuticals Details
2.1.2 Astellas Pharmaceuticals Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 Astellas Pharmaceuticals SWOT Analysis
2.1.4 Astellas Pharmaceuticals Product and Services
2.1.5 Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.2 GlaxoSmithKline
2.2.1 GlaxoSmithKline Details
2.2.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 GlaxoSmithKline SWOT Analysis
2.2.4 GlaxoSmithKline Product and Services
2.2.5 GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.3 Actavis
2.3.1 Actavis Details
2.3.2 Actavis Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Actavis SWOT Analysis
2.3.4 Actavis Product and Services
2.3.5 Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Pfizer SWOT Analysis
2.4.4 Pfizer Product and Services
2.4.5 Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.5 AstraZenenca
2.5.1 AstraZenenca Details
2.5.2 AstraZenenca Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 AstraZenenca SWOT Analysis
2.5.4 AstraZenenca Product and Services
2.5.5 AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
2.6 Salix Pharmaceuticals Ltd
2.6.1 Salix Pharmaceuticals Ltd Details
2.6.2 Salix Pharmaceuticals Ltd Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 Salix Pharmaceuticals Ltd SWOT Analysis
2.6.4 Salix Pharmaceuticals Ltd Product and Services
2.6.5 Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
3 Sales, Revenue and Market Share by Manufacturer
3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Manufacturer (2018-2019)
3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Manufacturer (2018-2019)
3.3 Market Concentration Rate
3.3.1 Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2019
3.3.2 Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer Market Share in 2019
3.4 Market Competition Trend
4 Global Market Analysis by Regions
4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Regions (2015-2020)
4.1.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Regions (2015-2020)
4.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.3 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.4 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.5 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
4.6 Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
5 North America by Country
5.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
5.1.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
5.1.2 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
5.2 United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
5.3 Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
5.4 Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6 Europe by Country
6.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
6.1.1 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
6.1.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
6.2 Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.3 UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.4 France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.5 Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
6.6 Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7 Asia-Pacific by Regions
7.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Regions
7.1.1 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Regions (2015-2020)
7.1.2 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Regions (2015-2020)
7.2 China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.3 Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.4 Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.5 India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.6 Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
7.7 Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
8 South America by Country
8.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
8.1.1 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
8.1.2 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
8.2 Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
8.3 Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9 Middle East & Africa by Countries
9.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Market Share by Country
9.1.1 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Country (2015-2020)
9.1.2 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Country (2015-2020)
9.2 Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9.3 Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9.4 Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
9.5 South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
10 Market Segment by Type
10.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Market Share by Type (2015-2020)
10.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Market Share by Type (2015-2020)
10.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Type (2015-2020)
11 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Segment by Application
11.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application (2015-2020)
11.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Application (2015-2020)
11.3 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Price by Application (2015-2020)
12 Market Forecast
12.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Revenue and Growth Rate (2021-2025)
12.2 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Regions (2021-2025)
12.2.1 North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.2 Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.3 Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.4 South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.2.5 Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025)
12.3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Type (2021-2025)
12.3.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2025)
12.3.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Type (2021-2025)
12.4 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast by Application (2021-2025)
12.4.1 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2025)
12.4.2 Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Application (2021-2025)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
15.3 Disclaimer
15.4 About US
Table 1. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Market Opportunities in Next Few Years
Table 5. Market Risks Analysis
Table 6. Market Drivers
Table 7. Astellas Pharmaceuticals Basic Information, Manufacturing Base and Competitors
Table 8. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 9. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 10. Astellas Pharmaceuticals SWOT Analysis
Table 11. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 12. Astellas Pharmaceuticals Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 13. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 14. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 15. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 16. GlaxoSmithKline SWOT Analysis
Table 17. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 18. GlaxoSmithKline Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 19. Actavis Basic Information, Manufacturing Base and Competitors
Table 20. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 21. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 22. Actavis SWOT Analysis
Table 23. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 24. Actavis Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 25. Pfizer Basic Information, Manufacturing Base and Competitors
Table 26. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 27. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 28. Pfizer SWOT Analysis
Table 29. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 30. Pfizer Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 31. AstraZenenca Basic Information, Manufacturing Base and Competitors
Table 32. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 33. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 34. AstraZenenca SWOT Analysis
Table 35. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 36. AstraZenenca Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 37. Salix Pharmaceuticals Ltd Basic Information, Manufacturing Base and Competitors
Table 38. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Major Business
Table 39. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Total Revenue (USD Million) (2018-2019)
Table 40. Salix Pharmaceuticals Ltd SWOT Analysis
Table 41. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Product and Services
Table 42. Salix Pharmaceuticals Ltd Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales, Price, Revenue, Gross Margin and Market Share (2018-2019)
Table 43. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Manufacturer (2018-2019) (K MT)
Table 44. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Manufacturer (2018-2019) (USD Million)
Table 45. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Regions (2015-2020) (K MT)
Table 46. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions (2015-2020)
Table 47. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 48. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 49. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Table 52. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 53. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 54. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 55. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Regions (2015-2020) (K MT)
Table 56. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions (2015-2020)
Table 57. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Regions (2015-2020) (USD Million)
Table 58. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 59. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 60. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 61. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Table 62. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Countries (2015-2020) (K MT)
Table 63. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Table 64. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Countries (2015-2020) (USD Million)
Table 65. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Table 66. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Type (2015-2020) (K MT)
Table 67. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Type (2015-2020)
Table 68. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue by Type (2015-2020) (USD Million)
Table 69. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Share by Type (2015-2020)
Table 70. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales by Application (2015-2020) (K MT)
Table 71. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Share by Application (2015-2020)
Table 72. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Regions (2021-2025) (K MT)
Table 73. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Regions (2021-2025)
Table 74. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Type (2021-2025) (K MT)
Table 75. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Type (2021-2025)
Table 76. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Forecast by Application (2021-2025)
Table 77. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Share Forecast by Application (2021-2025)
Table 78. Direct Channel Pros & Cons
Table 79. Indirect Channel Pros & Cons
Table 80. Distributors/Traders/ Dealers List
List of Figures
Figure 1. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Picture
Figure 2. Global Sales Market Share of Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs by Type in 2019
Figure 3. Preface Picture
Figure 4. Eluxadoline Picture
Figure 5. Alosetron Picture
Figure 6. Rifaximin Picture
Figure 7. Loperamide Picture
Figure 8. Diphenoxylate + Atropine Picture
Figure 9. Dicyclomine and Hyoscyamine Picture
Figure 10. Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Application in 2018
Figure 11. Hospitals Picture
Figure 12. Clinics Picture
Figure 13. Others Picture
Figure 14. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Status and Outlook (2015-2025) (USD Million)
Figure 15. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 16. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 17. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 18. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 19. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 20. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 21. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 22. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 23. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 24. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 25. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 26. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 27. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 28. Australia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025) (USD Million)
Figure 29. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 30. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 31. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 32. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 33. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue (Value) and Growth Rate (2015-2025)
Figure 34. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Manufacturer in 2019
Figure 35. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Manufacturer in 2019
Figure 36. Top 3 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 37. Top 6 Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Manufacturer (Revenue) Market Share in 2019
Figure 38. Key Manufacturer Market Share Trend
Figure 39. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 40. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 41. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions (2015-2020)
Figure 42. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions in 2018
Figure 43. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 44. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 45. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 46. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 47. Middle East & Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020)
Figure 48. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 49. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries (2015-2020)
Figure 50. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries in 2018
Figure 51. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020) (USD Million)
Figure 52. North America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2018
Figure 53. United States Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 54. Canada Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 55. Mexico Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 56. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 57. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Figure 58. Europe Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2019
Figure 59. Germany Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 60. UK Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 61. France Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 62. Russia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 63. Italy Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 64. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 65. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Regions 2019
Figure 66. Asia-Pacific Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Regions 2019
Figure 67. China Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 68. Japan Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 69. Korea Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 70. India Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 71. Southeast Asia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 72. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 73. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries in 2019
Figure 74. South America Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2019
Figure 75. Brazil Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 76. Argentina Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 77. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2015-2020) (USD Million)
Figure 78. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales Market Share by Countries in 2019
Figure 79. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries (2015-2020)
Figure 80. Middle East and Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue Market Share by Countries in 2019
Figure 81. Saudi Arabia Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 82. Egypt Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 83. Turkey Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 84. South Africa Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2015-2020) (K MT)
Figure 85. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Sales and Growth Rate (2021-2025) (K MT)
Figure 86. Global Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Revenue and Growth Rate (2021-2025) (USD Million)
Figure 87. North America Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 88. Europe Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 89. Asia-Pacific Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 90. South America Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 91. Middle East & Africa Sales Irritable Bowel Syndrome with Diarrhea (IBS-D) Drugs Market Forecast (2021-2025) (K MT)
Figure 92. Sales Channel: Direct Channel vs Indirect Channel
便秘薬による過敏性腸症候群の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Irritable Bowel Syndrome with Constipation Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. …- 炎症性腸疾患治療薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Inflammatory Bowel Disease Drugs market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Inflammatory…
- 下痢薬の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Diarrhea Drug market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Diarrhea Drug market report pro…
- プロバイオティクスサプリメントの世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Probiotics Suppliment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Probiotics Suppliment m…
- ドライアイ症候群治療の世界市場 2020年：メーカー別、地域別、種類・用途別 Market Overview The global Dry Eye Syndrome Treatment market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 3.5% in the forecast period of 2020 to 2025 and will expected to reach USD 3616.1 million by 2025, from USD 3148 million in 2019. The Dry Eye Syn…